Boston Scientific announced the launch of its Cognis CRT-D device in China. The latest launch is part of the company's strategy to capitalize on emerging markets.

As of now, the Cognis CRT-D is the smallest implantable defibrillator of its kind. The launch of the device in China follows regulatory approval in both Europe and the United States. With a 10-year estimated life span, the device includes six different pacing configurations. In addition, the device features the company's HF Perspectiv diagnostic technology. With HF Perspectiv, physicians can monitor and chart how patients are responding to therapy.

While the latest launch spells good news for the company, global defibrillator sales at Boston Scientific continue a downward trend. In its last quarter, the company's defibrillator revenue dropped 3% to $213 million. However, emerging markets still hold lots of potential for the company. In its last quarter, emerging markets revenue increased by 29%. In particular, the company's presence in BRICs like Brazil, Russia, India and China continues to grow.

During its first quarter, Boston Scientific faced a net loss of $354 million. However, recent acquisitions in renal denervation and electrophysiology could help push the medtech giant forwards.

"The Boston Scientific CRT-D System provides clinicians with many implantation choices, including different forms of the left ventricular lead, which I believe drive a high success rate of CRT-D implantation," stated Professor Wei Hua, chief cardiovascular physician at Fuwai Hospital.